Analyst Ratings for [AXON] Axovant Sciences Ltd.

7/16/25	Initiated	Neutral	X
AXON Axon UBS
$820
7/8/25	Initiated	Outperform	X
AXON Axon Wolfe Research
2/20/25	Downgrades	Buy Hold	X
AXON Axon Craig Hallum
$625
2/19/25	Downgrades	Buy Neutral	X
AXON Axon Northcoast
1/8/25	Initiated	Buy	X
AXON Axon TD Cowen
$700
9/12/24	Reiterated	Mkt Outperform	X
AXON Axon JMP Securities
$375 $430
7/17/24	Initiated	Buy	X
AXON Axon BofA Securities
$380
7/17/24	Initiated	Buy	X
AXON Axon Jefferies
$385
4/10/24	Reiterated	Buy	X
AXON Axon Needham
$315 $400
3/13/24	Initiated	Buy	X
AXON Axon Argus
$380
8/22/23	Initiated	Equal-Weight	X
AXON Axon Morgan Stanley
$230
7/5/23	Resumed	Overweight	X
AXON Axon JP Morgan
$236
5/11/23	Upgrades	Neutral Overweight	X
AXON Axon JP Morgan
$236
3/8/23	Initiated	Buy	X
AXON Axon Goldman
$263
3/2/23	Downgrades	Overweight Neutral	X
AXON Axon JP Morgan
$224
2/17/23	Downgrades	Strong Buy Outperform	X
AXON Axon Raymond James
$223
9/15/22	Initiated	Overweight	X
AXON Axon Barclays
$147
5/23/22	Downgrades	Overweight Eq-Weight	X
AXON Axon Morgan Stanley
$120
5/10/22	Initiated	Outperform	X
AXON Axon Credit Suisse
$169
11/16/21	Upgrades	Hold Buy	X
AXON Axon Craig Hallum
$232
5/19/21	Upgrades	Mkt Perform Strong Buy	X
AXON Axon Raymond James
$150
2/12/21	Downgrades	Overweight Neutral	X
AXON Axon JP Morgan
$129 $179
12/17/18	Upgrades	Hold Buy	X
AXON Axovant Sciences Jefferies

AXON Axovant Sciences Ltd.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.